HOT NEWS
Genzyme
Genzyme Corp.Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

.

Genzyme RSS Channel

Title Filter     Display # 
# Article Title Hits
1 Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS) 1948
2 Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations 5503
3 Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro®) 7465
4 Mipomersen Data Presented at European Atherosclerosis Society Congress 7978
5 Genzyme Reports Financial Results for the Third Quarter of 2010 10477
6 Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC 11095
7 Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen 10573
8 Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population 10747
9 European Commission Approves Genzyme's Mozobil 11198
10 Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease 11771
11 Genzyme Receives Positive Opinion for European Approval of Mozobil 10093
12 Genzyme Reports Solid Financial Results for the First Quarter of 2009 9245
13 European Authorities Approve Larger-Scale Production of Genzyme's Myozyme 6724
14 Strong Fourth Quarter for Genzyme Concludes Productive Year 5710
15 Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth 3558